Literature DB >> 28435475

Linear and Bilateral Multinucleated Cell Angiohistiocytoma (MCAH).

Valeria Coco1, Cristina Guerriero1, Alessandro Di Stefani1, Ilaria Pennacchia2, Ketty Peris1.   

Abstract

BACKGROUND: Multinucleated Cell Angiohistiocytoma (MCAH) is a rare disease, first described by Smith and Wilson Jones in 1985. Since then, less than 100 cases have been reported in the literature. Clinically it is characterized by papules or plaques arising from a specific anatomical area such as lower extremities, dorsum of the hands and face. Some generalized cases have been reported. MAIN OBSERVATIONS: We report a case of 77-year-old woman who presented with multiple itching. reddish to violaceous, flat to domed-shaped plaques on the lower legs with symmetrical and bilateral distribution along the saphena veins. On dermoscopy examination only a red-violaceous homogeneous area was visible. Histology showed remarkable proliferation of dilated small vessels in the upper and mid dermis and bizarre-shaped multinucleate giant cells with scalloped cytoplasm that were intermingled with numerous mononucleated spindle cells. Many mast cells containing the characteristic granules were also detected, often adjacent to the multinucleate cells. Based on the clinico-pathologic findings the diagnosis of MCAH was established.
CONCLUSIONS: To our knowledge, this is the first documented case of MCAH with a bilateral and linear pattern disposed on the lower limbs, following the saphena veins. In this patient chronic trauma induced by ambulation might have contributed to development of the lesions.

Entities:  

Keywords:  Kaposi sarcoma; dermatofibroma; dermoscopy; mast cells; multinucleated cell angiohistiocytoma; nodule

Year:  2016        PMID: 28435475      PMCID: PMC5392244          DOI: 10.3315/jdcr.2016.1237

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  15 in total

1.  Estrogen receptor alpha overexpression in multinucleate cell angiohistiocytoma: new insights into the pathogenesis of a reactive process.

Authors:  Anna Maria Cesinaro; Luca Roncati; Antonio Maiorana
Journal:  Am J Dermatopathol       Date:  2010-10       Impact factor: 1.533

2.  Multinucleate cell angiohistiocytoma: treatment using intense pulsed light.

Authors:  Beatriz Fernández-Jorge; Jesús del Pozo; Jesús García-Silva; Juan M Barja; M Teresa Yebra-Pimentel; Eduardo Fonseca
Journal:  Dermatol Surg       Date:  2009-04-28       Impact factor: 3.398

3.  Multinucleate cell angiohistiocytoma: a report of two cases.

Authors:  F Aloi; C Solaroli; C Tomasini; M Pippione
Journal:  J Eur Acad Dermatol Venereol       Date:  1998-07       Impact factor: 6.166

4.  Multinucleated cells angiohistiocytoma: a reactive lesion?

Authors:  Julien Calderaro; Luc Rethers; Nicolas Ortonne
Journal:  Am J Dermatopathol       Date:  2010-06       Impact factor: 1.533

5.  [Multinucleated cell angiohistiocytoma. Report of 6 cases].

Authors:  C Le Cam-Savin; A Dallot; P Chemaly; A Martin; L Choudat; J Amouroux
Journal:  Ann Pathol       Date:  1996-12       Impact factor: 0.407

6.  Generalized Multinucleate Cell Angiohistiocytoma.

Authors:  Jennifer A E Doane; Kerri Purdy; Sylvia Pasternak
Journal:  J Cutan Med Surg       Date:  2015-03-13       Impact factor: 2.092

Review 7.  Cutaneous vascular proliferations. Part III. Malignant neoplasms, other cutaneous neoplasms with significant vascular component, and disorders erroneously considered as vascular neoplasms.

Authors:  L Requena; O P Sangueza
Journal:  J Am Acad Dermatol       Date:  1998-02       Impact factor: 11.527

8.  Multinucleate-cell angiohistiocytoma occurring in a patient with mycosis fungoides.

Authors:  R S Bader; G H Telang; E C Vonderheid
Journal:  Cutis       Date:  1999-03

9.  [Multinucleate cell angiohistiocytoma].

Authors:  M Laturnus; M Megahed
Journal:  Hautarzt       Date:  2010-05       Impact factor: 0.751

10.  Multinucleate cell angiohistiocytoma: treatment with argon laser.

Authors:  D Kopera; J Smolle; H Kerl
Journal:  Br J Dermatol       Date:  1995-08       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.